Drug Trial Radar · NCT04488081
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Jul 31, 2020
Primary completion
Jul 31, 2028
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- QuantumLeap Healthcare CollaborativeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of California, San Francisco; Emory University; University of Alabama at Birmingham; University of Colorado, Denver; University of Southern California; Yale University; Wake Forest University Health Sciences; Long Beach Memorial Medical Center; Georgetown University; University of California, Davis; Main Line Health; DHR Health Institute for Research and Development; University of California, Irvine; University of Michigan; West Virginia University; University of Miami; University Hospitals Cleveland Medical Center; M.D. Anderson Cancer Center
- First posted
- Jul 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Conditions
- COVID-19
Interventions
RemdesivirDrug
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Imatinib MesylateDrug
Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
DexamethasoneDrug
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
CenicrivirocDrug
Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
IcatibantDrug
Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
ApremilastDrug
oral, 30 mg bid × 14 days.
dornase alfaBiological
For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first. For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first.
CelecoxibDrug
Oral: 400 mg BID for 7 days.
FamotidineDrug
Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
IC14Biological
intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
AviptadilDrug
Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
narsoplimabBiological
Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
CyproheptadineDrug
4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
CyclosporineDrug
Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19.Time frame: Up to 28 days
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
UC Davis Medical Center
Davis, California
UC Irvine Medical Center
Irvine, California
Long Beach Memorial Medical Center
Long Beach, California
Kaiser LAMC
Los Angeles, California
University of Southern California
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
University of California San Francisco (UCSF)
San Francisco, California
University of Colorado
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Stamford Health
Stamford, Connecticut
Georgetown University
Washington D.C., District of Columbia
University of Miami
Coral Gables, Florida
University of Florida
Gainesville, Florida
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University of Michigan
Ann Arbor, Michigan
Corewell Health
Grand Rapids, Michigan
Mercy Hospital Springfield
Springfield, Missouri
Kalispell Regional Medical Center
Kalispell, Montana
Logan Health Medical Center
Kalispell, Montana
Virtua Mount Holly Hospital
Mount Holly, New Jersey
Virtua Voorhees Hospital
Voorhees Township, New Jersey
Columbia University Medical Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Montefiore Medical Center
The Bronx, New York
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina
University Hospital Cleveland Medical Center
Cleveland, Ohio
University of Pennsylvania (U Penn)
Philadelphia, Pennsylvania
Lankenau Medical Center (Mainline Health)
Wynnewood, Pennsylvania
Main Line Health - Lankenau Medical Center
Wynnewood, Pennsylvania
Sanford Health
Souix Falls, South Dakota
DHR Health
Edinburg, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
WVU Medicine
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.